Literature DB >> 27468884

Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis.

Y Wang, J Sun, R Zheng, Q Shao, W Gao, B Song, X Chen, X Qu.   

Abstract

The clinical relevance of regulatory T cell (Treg) infiltration in breast cancer (BC) remains controversial, and no recent meta-analysis has been published on this subject. Our aim was to identify the precise relationship between Tregs and the prognosis and clinic-pathological features of BC. Eligible articles were identified with a MEDLINE database search over a period up to March 2015. Our meta-analysis was performed using STATA software 11.0 and Review Manager 5.3. The correlations between Treg infiltration and clinico-pathological features and BC prognosis were analyzed. Subgroup and sensitivity analyses, as well as meta-regression, were conducted. Eighteen published studies (including 8,562 patients) were eligible. Overall survival (OS) and disease-, recurrence-, and progression-free survival (DFS/RFS/PFS) were correlated with Treg infiltration (OR=2.03 (95% CI, 1.40-2.95; P=0.000) and 1.48 (95% CI, 1.00-2.19; P=0.050), respectively), including 3-, 5-, and 10-year mortality rates. In addition, low Treg infiltration was present in estrogen receptor (ER)-positive tumors (P=0.000), progesterone receptor (PR)-positive tumors (P=0.003), Her2-negative tumors (P=0.000) and histological grade I/II tumors (P=0.001). No publication bias was observed with the exception of OS. Subgroup analysis suggested that the mortality rate of the high Treg infiltration subgroup was increased compared with the low Treg infiltration subgroup among ER-positive patients. Treg infiltration indicated a poorer prognosis for BC and is related to ER, PR, and Her2 status and histological grade. Thus, Treg infiltration could help predict outcomes and guide clinical therapy.

Entities:  

Keywords:  breast cancer; estrogen receptor status; meta-analysis.; prognosis; regulatory T cells

Mesh:

Substances:

Year:  2016        PMID: 27468884     DOI: 10.4149/neo_2016_517

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  14 in total

1.  The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.

Authors:  Mohammad W Khan; Abdulrahman Saadalla; Ahmed H Ewida; Khalid Al-Katranji; Ghadier Al-Saoudi; Zachary T Giaccone; Fotini Gounari; Ming Zhang; David A Frank; Khashayarsha Khazaie
Journal:  Cancer Immunol Immunother       Date:  2017-09-05       Impact factor: 6.968

Review 2.  Influence of opioids on immune function in patients with cancer pain: from bench to bedside.

Authors:  Jason W Boland; A Graham Pockley
Journal:  Br J Pharmacol       Date:  2017-07-23       Impact factor: 8.739

Review 3.  Immunotherapy of cancer: targeting cancer during active disease or during dormancy?

Authors:  Syed Ammer Shah; Melika Zarei; Saeed H Manjili; Georgi Guruli; Xiang-Yang Wang; Masoud H Manjili
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

4.  Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.

Authors:  Chunlei Ge; Ruilei Li; Haifeng Song; Tao Geng; Jinyan Yang; Qinghua Tan; Linfeng Song; Ying Wang; Yuanbo Xue; Zhen Li; Suwei Dong; Zhiwei Zhang; Na Zhang; Jiyin Guo; Lin Hua; Siyi Chen; Xin Song
Journal:  BMC Cancer       Date:  2017-12-21       Impact factor: 4.430

Review 5.  Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Authors:  Anthos Christofides; Theodoros Karantanos; Kankana Bardhan; Vassiliki A Boussiotis
Journal:  Oncotarget       Date:  2016-12-20

6.  Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.

Authors:  Yasutaka Tono; Mikiya Ishihara; Yoshihiro Miyahara; Satoshi Tamaru; Hiroyasu Oda; Yoshiki Yamashita; Isao Tawara; Hiroaki Ikeda; Hiroshi Shiku; Toshiro Mizuno; Naoyuki Katayama
Journal:  Oncotarget       Date:  2018-02-16

7.  The Multifaceted Role of Regulatory T Cells in Breast Cancer.

Authors:  Kevin Kos; Karin E de Visser
Journal:  Annu Rev Cancer Biol       Date:  2020-12-04

8.  Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.

Authors:  Jenny Stenström; Ingrid Hedenfalk; Catharina Hagerling
Journal:  Breast Cancer Res       Date:  2021-02-18       Impact factor: 6.466

9.  Polyunsaturated fatty acid-based targeted nanotherapeutics to enhance the therapeutic efficacy of docetaxel.

Authors:  Thiruganesh Ramasamy; Pasupathi Sundaramoorthy; Hima Bindu Ruttala; Yongjoo Choi; Woo Hyun Shin; Jee-Heon Jeong; Sae Kwang Ku; Han-Gon Choi; Hwan Mook Kim; Chul Soon Yong; Jong Oh Kim
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer.

Authors:  Amany M Tawfeik; Ahmed Mora; Ahmed Osman; Manar M Moneer; Nabila El-Sheikh; Mohamed Elrefaei
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.